Phase 3 Immunoglobulin A Nephropathy Clinical Trials
5 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled228 locationsNCT06935357
Recruiting
Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals31 enrolled15 locationsNCT06994845
Recruiting
Phase 3
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Immunoglobulin A NephropathyIgANIgA Vasculitis+3 more
Alexion Pharmaceuticals, Inc.24 enrolled14 locationsNCT07024563
Not Yet Recruiting
Phase 3
A study of the effect and safety of sparsentan in the treatment of patients with immunoglobulin A nephropathy.
Immunoglobulin A Nephropathy
Retrophin, Inc.280 enrolled25 locationsACTRN12618001511224